Increased Complement Activation and Decreased ADAMTS13 Activity Are Associated with Genetic Susceptibility in Patients with Preeclampsia/HELLP Syndrome Compared to Healthy Pregnancies: An Observational Case-Controlled Study

• Published in: Journal of personalized medicine Vol. 14; no. 4; p. 387
• Main Authors: Venou, Theodora-Maria, Vetsiou, Evangelia, Varelas, Christos, Daniilidis, Angelos, Psarras, Kyriakos, Koravou, Evaggelia-Evdoxia, Koutra, Maria, Touloumenidou, Tasoula, Tsolakidis, Vasilis, Papalexandri, Apostolia, Minti, Fani, Mandala, Evdokia, Dinas, Konstantinos, Vlachaki, Efthymia, Gavriilaki, Eleni
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2024
• Subjects: Blood platelets; Blood pressure; Comparative analysis; Complement activation; Complement system; Disease susceptibility; Enzymes; Genes; Genetic aspects; Genetic diversity; Genetic research; Hypertension; Hypotheses; Liver; Liver diseases; MASP-2 protein; Medical research; Medicine, Experimental; Pathogenesis; Pathophysiology; Patients; Placenta; Pre-eclampsia; Preeclampsia; Pregnancy; Pregnancy complications; Pregnant women; Proteinuria; Risk factors; Seizures; Seizures (Medicine); Statistical analysis; Urine; Womens health; Greece; Canada; United States > US; ADAMTS13; C5b-9; next-generation sequencing; complement system; pregnancy-associated liver disease; HELLP syndrome; preeclampsia
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm14040387

Preeclampsia is a progressive multi-systemic disorder characterized by proteinuria, critical organ damage, and new-onset hypertension. It can be further complicated by HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), resulting in critical liver or renal damage, disseminated coagulation, and grand mal seizures. This study aimed to examine the involvement of ADAMTS13, von Willebrand, and the complement system in the pathogenesis of preeclampsia/HELLP syndrome. We studied 30 Caucasian preeclamptic pregnant women and a control group of 15 healthy pregnancies. Genetic sequencing of ADAMTS13 and complement regulatory genes (MiniSeq System, Illumina) was performed. The modified Ham test was used to check for complement activation, ADAMTS13 activity, von Willebrand antigen (vWFAg) levels, and soluble C5b-9 levels were measured. Patients with preeclampsia had a decreased ADAMTS13 activity and increased C5b-9 levels. The vWFAg was significantly correlated with ADAMTS13 activity (r = 0.497, = 0.003). Risk-factor variants were found in the genes of ADAMTS13, C3, thrombomodulin, CFB, CFH, MBL2, and, finally, MASP2. A portion of pregnant women with preeclampsia showed a decline in ADAMTS13 activity, correlated with vWFAg levels. These patients also exhibited an elevated complement activation and high-risk genetic variants in regulatory genes. Further research is needed to determine if these factors can serve as reliable biomarkers.